Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Mettler-Toledo (MTD) delivered solid Q1 2026 results with revenue up 7.2% YoY to $947.1M and EPS (diluted) up 6.7% to $8.33, though operating cash flow declined 28.1% and the company carries negative stockholders' equity due to its aggressive share buyback program.
Revenue
$947.13M
+7.17% YoY
EPS (Diluted)
$8.33
+6.66% YoY
Gross Margin
58.7%
-0.8 pts YoY
Source: SEC XBRL
MTD reported Q1 FY2026 revenue of $947.13M, up 7.2% year over year. Operating cash flow was $139.79M, down 28.1% year over year. MTD's fiscal Q1 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 11.46 | 10.90 | Beat +5.2% |
| Mar 2026This filing | 8.91 | 8.79 | Beat +1.4% |
| Dec 2025 | 13.36 | 12.93 | Beat +3.3% |
| Sep 2025 | 11.15 | 10.74 | Beat +3.8% |
Adjusted (non-GAAP) EPS of $8.91 versus the $8.79 analyst consensus — a +1.4% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $8.33.
Compiled by AI from this SEC filing
MTD grew total revenue 7.2% YoY to $947.1M in Q1 2026 (vs. $883.7M in Q1 2025), reflecting continued demand for precision instruments and services. This top-line momentum supported gross profit growth of 5.7% to $555.8M.
Source: 10-Q Income Statement (XBRL Financial Data)
Gross margin declined modestly by approximately 82 basis points YoY to 58.7% (from 59.5%), suggesting modest cost pressures or a slight shift in revenue mix. Despite this, the company maintained a strong absolute gross profit level of $555.8M.
Source: 10-Q Income Statement & Key Ratios (XBRL Financial Data)
R&D expenses grew 10.6% YoY to $51.3M, outpacing revenue growth of 7.2%, indicating MTD is investing more aggressively in product innovation and future capabilities. SG&A also rose 6.4% to $258.3M, broadly in line with revenue growth.
Source: 10-Q Income Statement (XBRL Financial Data)
Operating cash flow fell 28.1% YoY to $139.8M (from $194.4M), a notable deterioration that may reflect changes in working capital timing or higher cash operating costs. Investing cash outflows also increased sharply to -$31.3M from -$6.9M.
Source: 10-Q Cash Flow Statement (XBRL Financial Data)
MTD repurchased $206.3M in shares during Q1 2026, slightly below the $218.7M in Q1 2025 (-5.7% YoY), continuing its capital return strategy that has resulted in negative stockholders' equity of -$41.9M. This reflects the company's long-standing policy of returning capital to shareholders through buybacks rather than dividends.
Source: 10-Q Cash Flow Statement & Balance Sheet (XBRL Financial Data)
Compiled by AI from this SEC filing · 2 high, 3 medium, 0 low
MTD's stockholders' equity stands at -$41.9M as of Q1 2026, a structural feature driven by cumulative share repurchases exceeding retained earnings. While improving from -$182.0M a year ago, this balance sheet structure means the company is technically insolvent on a book-value basis and relies heavily on continued strong cash generation to service its obligations.
Source: 10-Q Balance Sheet (XBRL Financial Data)
Long-term debt increased 14.3% YoY to $2.16B, growing faster than total assets (+13.4%) and revenue (+7.2%). With negative equity, the debt-to-equity ratio is not meaningful in traditional terms (-88.6x), but the absolute debt load creates refinancing and interest rate risk if business conditions deteriorate.
Source: 10-Q Balance Sheet & Key Ratios (XBRL Financial Data)
Operating cash flow declined sharply by 28.1% YoY to $139.8M, even as net income grew 3.6% to $169.5M. This divergence between earnings and cash generation may indicate working capital headwinds or one-time items, and if sustained, could constrain the company's ability to fund buybacks, debt service, and capital expenditures simultaneously.
Source: 10-Q Cash Flow Statement (XBRL Financial Data)
Gross margin contracted approximately 82 basis points YoY to 58.7%, suggesting potential cost inflation or pricing pressure in certain product lines. If this trend continues, it could weigh on operating profitability even as revenue grows.
Source: 10-Q Key Ratios (XBRL Financial Data)
MTD spent $206.3M on share repurchases in Q1 2026 while generating only $139.8M in operating cash flow, meaning buybacks exceeded operating cash flow by approximately $66.5M. This gap requires drawing on existing cash balances or additional borrowing, adding financial leverage risk over time.
Source: 10-Q Cash Flow Statement (XBRL Financial Data)
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $M | 947.13 $M | 883.74 $M | +7.17% |
Gross Profit $M | 555.82 $M | 525.88 $M | +5.69% |
Net Income $M | 169.45 $M | 163.59 $M | +3.59% |
EPS (Basic) $ | 8.35 $ | 7.84 $ | +6.51% |
EPS (Diluted) $ | 8.33 $ | 7.81 $ | +6.66% |
R&D Expense $M | 51.28 $M | 46.35 $M | +10.64% |
SG&A Expense $M | 258.33 $M | 242.80 $M | +6.40% |
Answers draw on this SEC filing and the data on this page
In Q2 FY2024, MTD delivered 4.5% year-over-year revenue growth to $1.03B and a 15.1% increase in net income to $232.9M, aided by a net $24.6M one-time tariff refund benefit alongside steady laboratory and industrial product demand.
MTD delivered steady FY2025 growth with revenue rising 4.0% to $4.03B and EPS (diluted) up 3.9% to $42.05, though margins faced modest pressure and the company continues to operate with negative stockholders' equity driven by aggressive share buybacks.
Other companies in Life Sciences Tools & Services